Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan; Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.
Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan; Department of Radiation Oncology, Fourth Hospital of China Medical University, Shenyang, China.
Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):313-21. doi: 10.1016/j.ijrobp.2014.02.011. Epub 2014 Mar 28.
To investigate whether high-dose radiation to the pulmonary artery (PA) affects overall survival (OS) in patients with non-small cell lung cancer (NSCLC).
Patients with medically inoperable/unresectable NSCLC treated with definitive radiation therapy in prospective studies were eligible for this study. Pulmonary artery involvement was defined on the basis of pretreatment chest CT and positron emission tomography/CT fusion. Pulmonary artery was contoured according to the Radiation Therapy Oncology Group protocol 1106 atlas, and dose-volume histograms were generated.
A total of 100 patients with a minimum follow-up of 1 year for surviving patients were enrolled: 82.0% underwent concurrent chemoradiation therapy. Radiation dose ranged from 60 to 85.5 Gy in 30-37 fractions. Patients with PA invasion of grade ≤2, 3, 4, and 5 had 1-year OS and median survival of 67% and 25.4 months (95% confidence interval [CI] 15.7-35.1), 62% and 22.2 months (95% CI 5.8-38.6), 90% and 35.8 months (95% CI 28.4-43.2), and 50% and 7.0 months, respectively (P=.601). Two of the 4 patients with grade 5 PA invasion died suddenly from massive hemorrhage at 3 and 4.5 months after completion of radiation therapy. Maximum and mean doses to PA were not significantly associated with OS. The V45, V50, V55, and V60 of PA were correlated significantly with a worse OS (P<.05). Patients with V45 >70% or V60 >37% had significantly worse OS (13.3 vs 37.9 months, P<.001, and 13.8 vs 37.9 months, P=.04, respectively).
Grade 5 PA invasion and PA volume receiving more than 45-60 Gy may be associated with inferior OS in patients with advanced NSCLC treated with concurrent chemoradiation.
探讨高剂量肺动脉(PA)放疗是否会影响非小细胞肺癌(NSCLC)患者的总生存期(OS)。
本研究纳入了在前瞻性研究中接受根治性放疗的不能手术/不能切除的 NSCLC 患者。根据预处理胸部 CT 和正电子发射断层扫描/CT 融合,定义肺动脉受累。根据放射治疗肿瘤学组协议 1106 图谱勾画肺动脉,并生成剂量-体积直方图。
共纳入 100 例至少随访 1 年的存活患者:82.0%的患者接受了同期放化疗。放疗剂量为 60 至 85.5Gy,分为 30-37 个分次。PA 侵犯程度为≤2、3、4、5 级的患者 1 年 OS 和中位生存期分别为 67%和 25.4 个月(95%置信区间[CI] 15.7-35.1)、62%和 22.2 个月(95%CI 5.8-38.6)、90%和 35.8 个月(95%CI 28.4-43.2)和 50%和 7.0 个月(P=.601)。4 名 5 级 PA 侵犯患者中,有 2 人在放疗结束后 3 个月和 4.5 个月时因大出血突然死亡。PA 的最大和平均剂量与 OS 无显著相关性。PA 的 V45、V50、V55 和 V60 与较差的 OS 显著相关(P<.05)。V45 >70%或 V60 >37%的患者 OS 显著更差(13.3 与 37.9 个月,P<.001,和 13.8 与 37.9 个月,P=.04)。
在接受同期放化疗的晚期 NSCLC 患者中,5 级 PA 侵犯和接受 45-60Gy 以上剂量的 PA 体积可能与较差的 OS 相关。